Start here if you're new
what it is
Monopar develops cancer drugs and scan agents, with 4 programs mostly before the market.
how it gets paid
Last year Monopar Therapeutics made $0 in revenue.
what just happened
Monopar reported $0 in revenue and -$1.21 EPS in the latest quarter.
At a glance
B balance sheet — gets the job done, barely
55/100 earnings predictability — expect surprises
-$4.11 fy2024 eps est
0.6 beta
~$403M market cap
xvary composite: 48/100 — below average
What they do
Monopar develops cancer drugs and scan agents, with 4 programs mostly before the market.
Monopar runs 4 programs with 14 employees and $0 long-term debt. That is a tiny team carrying a $403M market cap. You are paying for 1 live clinical asset and 3 earlier shots, not revenue.
How they make money
$0
annual revenue
The products that matter
lead clinical asset
ALXN1840
the stock's main bet
This is the program doing the heavy lifting. If ALXN1840 clears the bar, Monopar starts looking like a commercial story. If it misses, the rest of the page gets a lot shorter.
the thesis
balance sheet reality
cash runway
not disclosed here
The source page does not give you a clean cash-runway figure. That matters because in biotech, time is a product. If you cannot fund the wait, you do not get to see the thesis play out.
the catch
second layer of upside
radiopharma pipeline
early-stage optionality
Every small biotech wants to be more than one program. This bucket is where that claim lives. Right now, it is backup story, not primary valuation support.
plan b
Key numbers
$58.27
share price
You are paying $58.27 for a company with $0 annual sales.
$403M
market cap
That is the full price tag for a 14-person biotech.
$0
annual revenue
No customers means the stock depends on trial data, not sales growth.
$0M
long-term debt
Zero debt helps, but it also means the company leans on equity financing and future trial wins.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for MNPR right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Monopar reported $0 in revenue and -$1.21 EPS in the latest quarter.
Revenue stayed at $0, which is normal for a clinical-stage biotech and brutal for the stock math. The company is still spending to advance 4 programs, and that keeps losses on the page.
$0M
revenue
-$1.21
eps
-$4.11
fy eps
zero sales
The whole quarter still had $0 of sales, so the stock is trading on trial updates, not customer demand.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
MNPR does not have the luxury of hiding its weak spots. The company has $0 revenue, one program doing most of the narrative work, and a stock price already carrying real optimism. If you own it, these are the failure points that matter.
med
ALXN1840 fails to clear the bar
This is the main kill criterion. If the lead program disappoints on efficacy, safety, or regulatory path, the bull case stops being a valuation debate and starts being a survival debate.
Impact: the market would likely reprice MNPR as a pre-revenue biotech without its lead reason to exist.
med
Time runs longer than cash
The source page does not give a clean runway figure. That absence matters. If timelines slip and capital has to be raised before a major proof point, existing holders usually pay for that patience through dilution.
Impact: even decent clinical progress can translate into a worse stock if new shares arrive at the wrong moment.
med
The market already prices in more than the business has earned
At roughly $403M market cap and $0 revenue, you are not buying proven cash flow. You are buying a probability distribution. If conviction cools before evidence improves, multiple compression does the damage even without a formal clinical miss.
Impact: the stock does not need catastrophic news to fall. It only needs the market to demand harder proof.
What would change our mind on the cautious view: clear ALXN1840 proof that materially improves the approval odds, plus enough balance-sheet visibility to get there without rushed financing. Without those two pieces, this stays a story stock with real downside.
source: institutional data · regulatory filings · risk analysis
Pay attention to
trend
whether ALXN1840 becomes a business instead of a thesis
This is the headline test. If the next meaningful update strengthens the program's odds, the stock's story improves fast. If it does not, the market cap starts looking expensive for a company with $0 revenue.
calendar
the next management update
Use the next update to judge pace, not polish. In biotech, a clean slide deck is decoration. You want a clearer path, tighter timelines, and less ambiguity about what comes next.
risk
financing pressure before the next proof point
Here is the thing: zero debt is nice, but it does not finance a trial by itself. If you see signs that capital has to be raised before the core catalyst, your risk-reward changes immediately.
metric
29.93% short interest
That number tells you the stock has a built-in argument. A good update forces shorts to move. A weak one tells you why they were there in the first place.
Analyst rankings
short-term outlook
mixed
target data exists, but conviction is thin. in human-speak, analysts see upside only if the clinical story cooperates.
risk profile
volatile
Price stability is 5 / 100 and short interest is 29.93%. That is a stock built for swings, not sleep.
chart momentum
catalyst-led
The chart is secondary. This name moves when the underlying thesis changes, not when a moving average feels inspired.
earnings predictability
55/100
That is middling because pre-revenue biotech numbers are less about stable operations and more about timing, spending, and trial cadence.
source: institutional data
Institutional activity
institutional ownership data for MNPR is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$58
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive